| 0 (0%) | 12-26 21:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.82  |
1-year : | 13.19 |
| Resists | First : | 10.98 |
Second : | 11.3 |
| Pivot price | 10.81 |
|||
| Supports | First : | 10.47 |
Second : | 8.71 |
| MAs | MA(5) : | 10.64 |
MA(20) : | 10.87 |
| MA(100) : | 10.75 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 15.4 |
| RSI | RSI(14): 31 |
|||
| 52-week | High : | 11.65 | Low : | 9.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BHV ] has closed above bottom band by 4.3%. Bollinger Bands are 35.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.6 - 10.66 | 10.66 - 10.71 |
| Low: | 10.32 - 10.4 | 10.4 - 10.47 |
| Close: | 10.39 - 10.52 | 10.52 - 10.61 |
Fri, 26 Dec 2025
Key facts: Biohaven Ltd. develops BHV-7000 for epilepsy; J.P. Morgan reports poor trial results - TradingView — Track All Markets
Fri, 26 Dec 2025
Biohaven's neuropsychiatric hopeful hits another wall - FirstWord Pharma
Fri, 26 Dec 2025
Biohaven reports Phase II BHV-7000 trial results for MDD - Clinical Trials Arena
Thu, 25 Dec 2025
Biohaven (BHVN) Valuation Check After BHV-1510 Cancer Data and BHV-7000 Pipeline Shift - simplywall.st
Thu, 25 Dec 2025
Biohaven: Phase 2 Proof-of-concept Study With BHV-7000 Fails To Meet Primary Endpoint - Nasdaq
Wed, 24 Dec 2025
Depression drug trial falls short as Biohaven turns to obesity and epilepsy - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -0.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.93 |
| Profit Margin | -106.1 % |
| Operating Margin | 65.8 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | -8.1 % |
| Qtrly Rev. Growth | -1.4 % |
| Gross Profit (p.s.) | 0.88 |
| Sales Per Share | 0.88 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -11.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 11.84 |
| Price to Cash Flow | 16.98 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|